Nurix Therapeutics financials
$23.68+0.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 May 31 | Q1 '26 Feb 28 | Q4 '25 Nov 30 | Q3 '25 Aug 31 | Q2 '25 May 31 | Q1 '25 Feb 28 | Q4 '24 Nov 30 | Q3 '24 Aug 31 | Q2 '24 May 31 | Q1 '24 Feb 29 | Q4 '23 Nov 30 | Q3 '23 Aug 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $6.3M | $13.6M | $7.9M | $44.1M | $18.5M | $13.3M | $12.6M | $12.1M | $16.6M | $15.2M | $18.5M |
| Gross profit | $9.0M | $6.3M | $13.6M | $7.9M | $44.1M | $18.5M | $13.3M | $12.6M | $12.1M | $16.6M | $15.2M | $18.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$94.2M | -$92.5M | -$83.1M | -$91.4M | -$48.3M | -$62.9M | -$64.7M | -$54.6M | -$48.5M | -$45.2M | -$45.3M | -$40.0M |
| Net income | -$89.5M | -$87.2M | -$78.2M | -$86.4M | -$43.5M | -$56.4M | -$58.5M | -$49.0M | -$44.5M | -$41.5M | -$42.0M | -$37.0M |
| Net margin | −990.1% | −1394.3% | −576.1% | −1094.8% | −98.7% | −305.4% | −440.7% | −388.9% | −368.4% | −250.3% | −276.8% | −200.3% |
| Diluted EPS | $-0.81 | $-0.79 | $-0.82 | $-1.03 | $-0.52 | $-0.67 | $-0.75 | $-0.67 | $-0.71 | $-0.76 | $-0.77 | $-0.68 |
| EBITDA | -$91.9M | -$90.3M | -$81.0M | -$89.4M | -$46.1M | -$60.5M | -$62.1M | -$52.2M | -$46.2M | -$43.2M | -$45.3M | -$38.1M |
| Operating cash flow | -$96.6M | -$71.9M | -$67.8M | -$57.4M | -$63.2M | -$61.1M | -$48.8M | -$42.2M | -$39.7M | -$42.0M | $26.7M | -$41.1M |
| Free cash flow | -$98.5M | -$73.0M | -$73.0M | -$60.1M | -$65.8M | -$64.6M | -$50.9M | -$44.5M | -$41.6M | -$44.8M | $24.1M | -$43.6M |
| Diluted shares | 111.1M | 110.1M | 95.1M | 84.2M | 83.9M | 83.6M | 78.4M | 72.8M | 62.4M | 54.9M | 54.7M | 54.4M |
Balance sheet
| Period end | May 31 | Feb 28 | Nov 30 | Aug 31 | May 31 | Feb 28 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $67.7M | $71.2M | $247.0M | $78.4M | $84.3M | $75.9M |
| Short-term investments | $375.8M | $469.5M | $346.0M | $350.4M | $401.5M | $473.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $535.5M | $636.1M | $688.1M | $522.5M | $591.6M | $615.0M |
| Total liabilities | $132.9M | $155.2M | $149.4M | $150.2M | $144.0M | $134.1M |
| Shareholders' equity | $402.6M | $480.9M | $538.7M | $372.3M | $447.6M | $480.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology